title: Efficacy of long-term lanreotide treatment in patients with acromegaly.
abstract: We investigated the effectiveness of lanreotide for the treatment of active acromegaly in a retrospectively multicenter case series including 53 patients (24 male, 29 female; mean age at diagnosis, 49.5 +/- 13.9 years) with acromegaly treated with lanreotide in nine different centers. Mean tumor diameter was 20 +/- 13 mm; mean basal levels of growth hormone (GH) and insulin-like growth factor I (IGF-I) were 21.3 +/- 26.3 and 579 +/- 177 mug/l, respectively. The primary mode of treatment was surgery in 70% of patients. Twenty-nine patients received only lanreotide (Prolonged Release, Autogel), whereas 24 subjects were also treated with octreotide at another treatment stage. Primary therapy with lanreotide was administered in five patients. Maximal monthly dose of lanreotide Autogel (n = 44) was 60 mg in 45%, 90 mg in 26%, 120 mg in 21% and 180 mg in 8%. During 36 months of lanreotide treatment, mean IGF-I levels decreased from 443 +/- 238 to 276 +/- 147 mug/l (P < 0.001), and mean GH levels, from 5.2 +/- 6.4 to 3.2 +/- 3.0 mug/l (P < 0.001). IGF-I levels normalized in 51% of patients and decreased by >50% towards normal in 32%; the normalization rate was higher in women (65%) than men (33%, P = 0.04). Safe random GH levels (</=2 mug/l) were achieved in 49% of patients. Both IGF-I normalization and safe GH levels were reached in 32% of the cohort. Lanreotide is an effective treatment for active acromegaly. Female sex was associated with higher rates of IGF-I normalization.
authors.affiliation: Unit of Endocrinology & Diabetes, Hillel Yaffe Medical Center, Hadera, Israel.
authors.forename: Yoel
authors.initials: Y
authors.lastname: Toledano
authors.forename: Liat
authors.initials: L
authors.lastname: Rot
authors.forename: Yona
authors.initials: Y
authors.lastname: Greenman
authors.forename: Sophia
authors.initials: S
authors.lastname: Orlovsky
authors.forename: Yulia
authors.initials: Y
authors.lastname: Pauker
authors.forename: David
authors.initials: D
authors.lastname: Olchovsky
authors.forename: Achia
authors.initials: A
authors.lastname: Eliash
authors.forename: Orit
authors.initials: O
authors.lastname: Bardicef
authors.forename: Ofa
authors.initials: O
authors.lastname: Makhoul
authors.forename: Gloria
authors.initials: G
authors.lastname: Tsvetov
authors.forename: Michal
authors.initials: M
authors.lastname: Gershinsky
authors.forename: Odile
authors.initials: O
authors.lastname: Cohen-Ouaqnine
authors.forename: Rosane
authors.initials: R
authors.lastname: Ness-Abramof
authors.forename: Zaina
authors.initials: Z
authors.lastname: Adnan
authors.forename: Jacob
authors.initials: J
authors.lastname: Ilany
authors.forename: Hadassah
authors.initials: H
authors.lastname: Guttmann
authors.forename: Mazal
authors.initials: M
authors.lastname: Sapir
authors.forename: Carlos
authors.initials: C
authors.lastname: Benbassat
authors.forename: Ilan
authors.initials: I
authors.lastname: Shimon
mesh_terms: D000172:Acromegaly / Q000188:drug therapy* / Q000378:metabolism; D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005260:Female; D019382:Human Growth Hormone / Q000378:metabolism; D006801:Humans; D008297:Male; D008875:Middle Aged; D010456:Peptides, Cyclic / Q000627:therapeutic use*; D012189:Retrospective Studies; D013002:Somatomedins / Q000378:metabolism; D013004:Somatostatin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D010456:Peptides, Cyclic; D013002:Somatomedins; C060347:lanreotide; D019382:Human Growth Hormone; D013004:Somatostatin